Gerinnungsstörungen bei Intensivpatienten: Diagnostik und Therapie

Zusammenfassung

Der Artikel fokussiert auf neuen Erkenntnissen bei der Behandlung von Blutungskomplikationen unter Antikoagulation mit einem NOAK, auf der Diagnostik und Therapie bei Heparin-induzierter Thrombozytopenie sowie auf der Indikation für eine Behandlung mit Plasmapräparaten bei Patienten mit Leberzirrhose. Er beschribt eine neue Behandlungsoption der erworbenen Hemmkörperhämophilie gegen Faktor VII.

Abstract

The phase III non-vitamin K dependent oral anticoagulants (NOAC) studies and recently published real world data on the use of dabigatran and rivaroxaban have shown that the bleeding profile in particular of intracranial and other life-threatening bleeding of NOAC is more favourable than that of warfarin. In case of a bleeding complication in a patient treated with a NOAC the recently updated EHRA practical guide offers management strategies. Idarucizumab, the specific antidot for dabigatran is approved to reverse the anticoagulant effect of dabigatran-treated patients who have serious bleeding and require an urgent procedure. Andexanet alfa, a specific antidot for direct and indirect factor Xa-inhibitors will be available in the future. The frequency of thrombocytopenia in ICU patients is high whereas the heparin induced thrombocytopenia (HIT) only counts for a small minority of patients with thrombocytopenia. To avoid an overdiagnosis of HIT a reliable and complete clinical and laboratory workup has to be performed. New immunoassays have been developed to provide results within a short period of time. These tests appear to have improved diagnostic accuracy compared with ELISAs in patients with suspected HIT and may reduce misdiagnosis and overtreatment. Acquired haemophilia (AH) is a rare and often life threatening bleeding disorder caused by autoantibodies against factor VIII. Susoctocog alfa is a B-domain deleted recombinant factor VIII porcine sequence that has recently been approved to treat severe bleeding in patients with AH. Susoctocog alfa offers the ability to effectively titrate and monitor dosing based on factor VIII activity levels.

Schlüsselwörter

NOAK - Antidot - HIT - Leberzirrhose - erworbene Hemmkörperhämophilie

Keywords

NOAK - reversal agents - HIT - liver cirrhosis - acquired haemophilia

• Literatur

• 1 Camm AJ, Amarenco P, Haas S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2015; pii: ehv466
• 2 Graham DJ, Reichman ME, Wernecke M et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-164
• 3 Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467-1507
• 4 Pollack Jr CV, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520
• 5 Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med 2015; 373: 2413-2424
• 6 Greinacher A. CLINICAL PRACTICE. Heparin-Induced Thrombocytopenia. N Engl J Med 2015; 373: 252-261
• 7 Warkentin TE. Heparin-induced thrombocytopenia. Curr Opin Crit Care 2015; 21: 576-585
• 8 Lo GK, Juhl D, Warkentin TE et al. Evaluation of pretest clinical score (4 T‘s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006; 4: 759-765
• 9 Berry C, Tcherniantchouk O, Ley EJ et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg 2011; 213: 10-17 discussion 17–18
• 10 Sun L, Gimotty PA, Lakshmanan S et al. Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis. Thromb Haemost 2016; 115
• 11 Keyl C, Zimmer E, Bek MJ et al. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia. Thromb Haemost 2016; 115
• 12 Goel R, Ness PM, Takemoto CM et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood 2015; 125: 1470-1476
• 13 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171
• 14 Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol 2013; 11: 1064-1074
• 15 Mallett SV, Chowdary P, Burroughs AK. Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 2013; 33: 961-974
• 16 Agarwal B, Wright G, Gatt A et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57: 780-786
• 17 Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 2087-2107
• 18 Shah NL, Intagliata NM, Northup PG et al. Procoagulant therapeutics in liver disease: a critique and clinical rationale. Nat Rev Gastroenterol Hepatol 2014; 11: 675-682
• 19 Villanueva C, Colomo A, Bosch A. Transfusion for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368: 1362-1363
• 20 Cugno M, Gualtierotti R, Tedeschi A et al. Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy. Autoimmun Rev 2014; 13: 40-48
• 21 Kruse-Jarres R, St-Louis J, Greist A et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia 2015; 21: 162-170